Compare GDC & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | ERNA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 7.8M |
| IPO Year | N/A | 2021 |
| Metric | GDC | ERNA |
|---|---|---|
| Price | $1.92 | $4.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 299.5K | 69.5K |
| Earning Date | 04-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.13 |
| 52 Week High | $9.92 | $15.88 |
| Indicator | GDC | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 43.18 |
| Support Level | $0.08 | $0.23 |
| Resistance Level | $2.07 | $7.94 |
| Average True Range (ATR) | 0.20 | 0.43 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 72.41 | 61.31 |
GD Culture Group Ltd operates and manages its business as a single segment and has one operating and reportable segment, the Virtual Content Production. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.